Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Greer BE, Bundy BN, Ozols RF, Fowler JA, Clarke-Pearson D, Burger RA, Mannel R, DeGeest K, Hartenbach EM, Baergen RN, Copeland LJ. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: A non-randomized comparison using an explanatory analysis: A Gynecologic Oncology Group study. Gynecologic Oncology. 2005 Oct;99(1):71-9.
Henry LR, Sigurdson E, Arciero CA, Watson JC. A disappearing hepatic infusion pump. Journal of Gastrointestinal Surgery. 2005 Jul;9(6):878-9.
Konski A, Hoffman J, Sigurdson E, Haluszka O, Engstrom P, Cheng JD, Cohen SJ, Watson JC, Eisenberg D, McGarrity E, Freedman G, Meropol NJ. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. SEMINARS IN ONCOLOGY. 2005 Jan;32(6):S63-S67.
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):667-71.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2005 Jan;96(1):67-71.
Mulcahy MF, Loehrer PJ, Meropol NJ, Rademaker AW, Benson AB. A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin. Oncology. 2005 Jan;68 (4-6):479-84.
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clinical Cancer Research. 2005 Aug;11(15):5342-6.
Siegelmann-Danieli N, Ben-Izhack O, Hanlon A, Ridge JA, Stein ME, Khandelwal V, Langer CJ. P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori. 2005 Jul;91(4):346-50.
Somer RA, Langer CJ. Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: Case report. Cancer Investigation. 2005 Mar;23(2):134-7.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
Werner-Wasik M, Langer C, Movsas B. Amifostine in chemoradiation therapy for non-small cell lung cancer: Review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Seminars in Oncology. 2005 Apr 03;32(2):S105-S108.
Anderson PR, Hanlon AL, McNeeley SW, Freedman GM. Low complication rates are achievable after postmastectomy breast reconstruction and radiation therapy. International Journal of Radiation Oncology Biology Physics. 2004 Jul;59(4):1080-7.
Ansell SM, Schilder RJ, Pieslor PC, Gordon LI, Emmanouilides C, Vo K, Czuczman MS, Witzig TE, Theuer C, Molina A. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature. Clinical Lymphoma. 2004 Dec;5(3):202-4.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004 Jan;67 (5-6):390-6.
Gervasoni JE, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer research. 2004 Sep;24(5A):2617-26.
Ibrahim D, Smith MR, Varterasian M, Karanes C, Millenson M, Yeslow G, Pemberton P, Lai P, Abrams J, Al-Katib A. Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma. Leukemia & lymphoma. 2004 Oct;45(10):2079-84.
Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. International Journal of Radiation Oncology Biology Physics. 2004 Dec;60(5):1373-8.
Langer C, Lilenbaum R. Patients with non-small cell lung cancer and poor performance status: A significant population with limited data. Seminars in Oncology. 2004 Dec 11;31(6):1-2.
Meyers MO, Meszoely IM, Hoffman JP, Watson JC, Ross E, Eisenberg BL. Is reporting of recurrence data important in pancreatic cancer?. Annals of Surgical Oncology. 2004 Mar;11(3):304-9.
Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphorna. Haematologica. 2004 Dec;89(12):1484-91.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy trial paclitaxel radiotherapy cancer carcinoma metastatic breast-cancer cisplatin survival treatment combination Oncology gemcitabine therapy apoptosis phase-iii trial previously irradiated patients daunrubicin overexpression multiple-myeloma pancreatic carcinoma cells metastatic colorectal-cancer activation RANDOMIZED CONTROLLED TRIAL brain metastases necrosis squamous-cell carcinoma mitoxantrone plus prednisone mutations 2nd PHASE-II relapsed Hodgkin lymphoma phase-iii complications minimization 1st relapse fraction radiotherapy placebo-controlled trial phase-ii breast-cancer term follow-up fluorouracil plus leucovorin pancreatic cancer DUCTAL ADENOCARCINOMA implant fdg-pet KeyWords Plus: folinic acid stem-cell transplantation randomized-trial responses gene oropharynx advanced stage ovarian cancer second-look laparotomy oncology CHEMOTHERAPY survival treatment leukemia cosmesis family escalation ovarian cancer cyclophosphamide topotecan GEMCITABINE postoperative radiotherapy interruptions zoledronic acid chronic lymphocytic-leukemia recurrent disease nonsmall cell lung cancer-chemotherapy-temozolomide-clinical response SURVIVAL metastases alpha-interferon fludarabine-low-grade NHL cancer-patients toxicity radiation-therapy prognostic factors CURATIVE RESECTION progression-free survival maintenance therapy final analysis prostate-cancer phase-ii trial radioimmunotherapy refractory prostate-cancer quality-of-life sponsored-working-group laparotomy autologous blood critical reassessment tram P53 immunohistochemistry-smoking-squamous cell carcinoma-tongue breast cancer combination chemotherapy disease patients resistance oxaliplatin group rtog trials neck-cancer sr-89 bone metastases doxorubicin advanced head interval CARCINOMA non-small-cell lung carcinoma cell-death cooperative-oncology-group tumor response first relapse 9-aminocamptothecin irinotecan recurrence 5-FLUOROURACIL primary peritoneal carcinoma expression thoracic radiotherapy expander resection advanced gastric-cancer immediate estramustine randomized-trials low-grade lung carcinoma cost analysis-secondary bone neoplasms-retrospective study canadian randomized-trial cell cycle arrest premenopausal women high-dose therapy docetaxel etoposide multicenter trial favorable patients oral capecitabine hepatic arterial infusion gastric cancer phase I trials-docetaxel chemosensitivity design metastasis end-points pain relief advanced follicular lymphoma impact salvage therapy clinical-trials RADIATION pamidronate ceramide generation rituximab
Last updated on Thursday, June 04, 2020